Healthcare [ 13/13 ] | Drug Manufacturers - General [ 60/164 ]
NASDAQ | Common Stock
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally.
The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.
It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies.
In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug.
Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development.
Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG.
It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies.
The company was founded in 1909 and is headquartered in Barcelona, Spain.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 2, 24 | 0.00 Decreased by -100.00% | - |
| Feb 29, 24 | 0.00 Decreased by -100.00% | 0.25 Decreased by -100.00% |
| Nov 2, 23 | 0.11 Increased by +N/A% | 0.22 Decreased by -50.00% |
| Jul 27, 23 | 0.16 Increased by +24.92% | 0.20 Decreased by -17.18% |
| May 15, 23 | 0.04 Increased by +N/A% | 0.16 Decreased by -72.47% |
| Feb 28, 23 | 0.06 Decreased by -43.47% | 0.15 Decreased by -57.61% |
| Nov 8, 22 | 0.00 Decreased by -100.00% | - |
| Jul 28, 22 | 0.13 Decreased by -45.00% | 0.29 Decreased by -54.84% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 1.60 B Increased by +3.66% | 59.54 M Increased by +33.63% | Increased by +3.73% Increased by +28.91% |
| Jun 30, 23 | 1.66 B Increased by +7.81% | 60.03 M Decreased by -33.54% | Increased by +3.61% Decreased by -38.36% |
| Mar 31, 23 | 1.71 B Increased by +86.47% | 20.07 M Increased by +110.75% | Increased by +1.17% Increased by +105.76% |
| Dec 31, 22 | 1.71 B Increased by +N/A% | 20.07 M Increased by +N/A% | Increased by +1.17% - |
| Sep 30, 22 | 1.54 B Increased by +N/A% | 44.56 M Increased by +N/A% | Increased by +2.89% - |
| Jun 30, 22 | 1.54 B Increased by +14.13% | 90.34 M Decreased by -34.00% | Increased by +5.86% Decreased by -42.17% |
| Mar 31, 22 | 918.52 M Decreased by -29.85% | -186.73 M Decreased by -183.62% | Decreased by -20.33% Decreased by -219.20% |
| Dec 31, 21 | N/A Decreased by -100.00% | N/A Decreased by -100.00% | - - |